Emtricitabine, 98%

Name: Emtricitabine, 98% | 143491-57-0
Brand: J&K Chemical
SKU: JK315507_5_G
Price: 21.9 USD
Availability: OutOfStock

Cat. No JK315507_5_G

Vendor: J&K Chemical

Product Information

Product Name

Emtricitabine, 98%

Brand Name

J&K

Product Number

315507

CAS

143491-57-0

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

60877

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Oral Lamivudine for Extended HIV Postnatal Prophylaxis

Publication Name: Paediatric drugs

Publication Date: 2026-03-03

DOI: 10.1007/s40272-026-00745-6

Estimating the percentage and number of people with indications for HIV pre-exposure prophylaxis (PrEP) within two key populations, Canada, 2021

Publication Name: Canadian journal of public health = Revue canadienne de sante publique

Publication Date: 2026-03-03

DOI: 10.17269/s41997-026-01170-5

From bench to bedside: stem cell therapy as a transformative approach against HIV

Publication Name: Molecular Biology Reports

Publication Date: 2026-02-27

DOI: 10.1007/s11033-026-11586-4

HIV Pre-exposure Prophylaxis at a Local Public Health Department in the Southern United States: Reducing Barriers, Increasing Access, and Lessons Learned

Publication Name: AIDS and Behavior

Publication Date: 2026-02-19

DOI: 10.1007/s10461-026-05048-y

Bictegravir/emtricitabine/tenofovir alafenamide/Covid-19 vaccine

Publication Name: Reactions Weekly

Publication Date: 2026-02-14

DOI: 10.1007/s40278-026-92514-9

Emtricitabine, 98%

Product Information

General Information

Safety Information

References Data Source From Pubchem

Oral Lamivudine for Extended HIV Postnatal Prophylaxis

Estimating the percentage and number of people with indications for HIV pre-exposure prophylaxis (PrEP) within two key populations, Canada, 2021

From bench to bedside: stem cell therapy as a transformative approach against HIV

HIV Pre-exposure Prophylaxis at a Local Public Health Department in the Southern United States: Reducing Barriers, Increasing Access, and Lessons Learned

Bictegravir/emtricitabine/tenofovir alafenamide/Covid-19 vaccine